Welcome to our dedicated page for Viridian Therapeutics news (Ticker: VRDN), a resource for investors and traders seeking the latest updates and insights on Viridian Therapeutics stock.
Viridian Therapeutics, Inc. (Nasdaq: VRDN) is a Waltham, Massachusetts-based biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases. News about Viridian often centers on its late-stage programs in thyroid eye disease (TED), regulatory milestones, clinical trial updates, and financing activities that support its pipeline and anticipated commercialization efforts.
Investors following VRDN news can expect frequent updates on veligrotug, Viridian’s intravenously delivered anti–IGF‑1R antibody for TED. Company announcements have highlighted the completion of two global phase 3 trials, THRIVE and THRIVE‑2, positive topline data, and the U.S. Food and Drug Administration’s acceptance of a Biologics License Application with Priority Review and a defined PDUFA target action date. News releases also discuss preparations for a potential commercial launch, including market access, medical affairs, and engagement with a core prescriber base.
Another key news theme is VRDN‑003 (elegrobart), a subcutaneous, half‑life extended anti‑IGF‑1R antibody in phase 3 trials REVEAL‑1 and REVEAL‑2 for active and chronic TED. Viridian’s press releases describe enrollment progress, anticipated topline data timing, and the design of VRDN‑003 for subcutaneous administration in a low‑volume autoinjector with every‑four‑week or every‑eight‑week dosing. Updates on Viridian’s FcRn inhibitor portfolio—including VRDN‑006 and VRDN‑008—cover proof‑of‑concept IgG reduction data, investigational new drug (IND) submissions, and preclinical head‑to‑head findings.
VRDN news also frequently includes corporate and financial developments, such as public equity offerings, royalty financing agreements, amended credit facilities, and collaboration and license agreements like the partnership with Kissei Pharmaceutical Co., Ltd. for veligrotug and VRDN‑003 in Japan. These disclosures provide context on how Viridian plans to fund its clinical programs and potential commercial launches. For a comprehensive view of Viridian’s evolving TED pipeline, autoimmune disease programs, and capital strategy, readers can review the ongoing stream of press releases, earnings updates, and SEC-reported events associated with the VRDN ticker.
Viridian Therapeutics (VRDN) announced positive topline data from its Phase 1/2 trial of VRDN-001, an anti-IGF-1R antibody for active thyroid eye disease (TED). In the latest cohort, 3 mg/kg showed significant improvements: 67% of patients were proptosis responders, and 56% overall responders. Across all cohorts, 71% were proptosis responders, with a favorable safety profile noted. The data support a planned once-monthly subcutaneous dosing for VRDN-002 and VRDN-003. The company is progressing towards pivotal trials and expects to advance its subcutaneous program as a convenient treatment option.
Viridian Therapeutics (NASDAQ: VRDN) announced that its CEO, Jonathan Violin, Ph.D., will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 2:15 p.m. PST in San Francisco. Alongside the presentation, a live Q&A session will begin at 2:35 p.m. PST. Investors can access the live webcast on the company's website, with a replay available until February 8, 2023. Viridian is focused on developing treatments for serious diseases, including ongoing clinical trials for VRDN-001 targeting thyroid eye disease.
Viridian Therapeutics (NASDAQ: VRDN) has enrolled its first patient in the global THRIVE Phase 3 trial, evaluating the investigational agent VRDN-001 for active thyroid eye disease (TED). The trial involves around 120 patients across 50 centers in North America and Europe, aiming for topline results by mid-2024. VRDN-001, a monoclonal antibody targeting IGF-1R, has shown promising efficacy in preliminary studies. The company also plans a second Phase 3 trial for chronic TED, further supporting its commitment to improving treatment options for patients.
Viridian Therapeutics (Nasdaq: VRDN) announced the grant of non-qualified stock options to an employee for 215,000 shares of common stock, approved by its Compensation Committee. This Inducement Grant, dated December 1, 2022, is outside the 2016 Equity Incentive Plan but adheres to its terms. The exercise price aligns with the stock's closing price on the grant date, and shares will vest over four years. Viridian focuses on treatments for serious diseases, with its lead program targeting thyroid eye disease (TED) through differentiated monoclonal antibodies.
Viridian Therapeutics, Inc. (NASDAQ: VRDN) will participate in the 5th Annual Evercore ISI HealthCONx Conference on December 1, 2022. The conference will feature a fireside chat at 10:30 a.m. ET, available via a live webcast on the company's website. Viridian is focused on developing innovative treatments for serious diseases, notably through its monoclonal antibody programs targeting thyroid eye disease (TED). Key products include VRDN-001, VRDN-002, and VRDN-003, which offer convenient dosing options for patients suffering from TED.
Viridian Therapeutics (NASDAQ: VRDN) reported significant progress in its Phase 1/2 trial of VRDN-001 for thyroid eye disease (TED), showing rapid clinical improvement after two infusions. The company has initiated the global Phase 3 THRIVE clinical program. As of September 30, 2022, cash and equivalents totaled $431 million, extending its financial runway into the second half of 2025. The third-quarter net loss increased to $28.9 million, up from $14.0 million year-over-year, primarily due to rising R&D and administrative expenses.
Viridian Therapeutics announced positive topline data from its Phase 1/2 trial of VRDN-001, an anti-IGF-1R antibody for thyroid eye disease (TED). Key findings include:
- 75% proptosis response rate
- 75% overall response rate
- Safety profile remains favorable at 20 mg/kg dose
The study supports the transition to a global Phase 3 THRIVE program, with proof-of-concept data for VRDN-002 expected in 2H23. The company is well-capitalized with $431M, securing operations into 2H25.
Viridian Therapeutics (NASDAQ: VRDN) will participate in the Guggenheim 4th Annual Neuro/Immunology Conference on November 15, 2022. The company will host a fireside chat at 1:35 p.m. ET. Investors can access the live webcast and subsequent replay through the company's Investors section. Viridian is focused on developing treatments for serious diseases, including thyroid eye disease.
Viridian Therapeutics, Inc. (NASDAQ: VRDN) will announce its financial results for Q3 2022 on November 14, 2022, before market opening. A conference call is scheduled for the same day at 8:00 a.m. ET, accessible via phone or live webcast. The company focuses on developing treatments for serious diseases, with its leading program, VRDN-001, targeting insulin-like growth factor-1 receptor for thyroid eye disease (TED). VRDN-002 and VRDN-003 are enhanced versions of this therapy, aimed at improving patient convenience.
Viridian Therapeutics presented promising data for VRDN-001, an anti-IGF-1R antibody, during three late-breaking presentations at the American Thyroid Association (ATA) 91st Annual Meeting. The Phase 1/2 trial showed an 83% proptosis response and significant reductions in clinical activity scores among patients with active thyroid eye disease (TED) after receiving two 10 mg/kg infusions. The pivotal program for VRDN-001 is scheduled to start this quarter, with additional data from the 20 mg/kg cohort expected soon.